Johnson & Johnson Snaps Six Days of Losing Streak

Seeking Alpha16:13 ET

GSK: Data Compares With Competitor Drug Johnson & Johnson's Darzalex

Dow Jones13:30 ET

GSK: Data Supports Potential for Blenrep Combinations to Become Standard of Care

Dow Jones13:30 ET

GSK: Data Is For Patients With Multiple Myeloma at or After First Relapse

Dow Jones13:30 ET

GSK: Blenrep Is Treatment for Relapsed/Refractory Multiple Myeloma

Dow Jones13:30 ET

GSK: Data Projects Patients on Blenrep Combination To Survive Nearly Three Years Longer Compared to Standard of Care

Dow Jones13:30 ET